Physician profile
Christopher A Brown
NPI 1194715813
$13,778.68
in general payments reported to CMS, 2019-2025
32 companies · $2,960 in 2025
The $2,960 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,177 · 2020: $1,064 · 2021: $1,557 · 2022: $2,045 · 2023: $1,993 · 2024: $2,984 · 2025: $2,960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,863 · Education: $73.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,863.47 |
| Education | $73.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,902.22 | 2019-2025 | Linzess, Viberzi, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,204.11 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Gilead Sciences, INC. | $1,226.30 | 2019-2025 | Epclusa, Livdelzi |
| Janssen Biotech, INC. | $1,058.41 | 2019-2025 | Tremfya, Stelara, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $980.52 | 2019-2025 | Entyvio |
| Ironwood Pharmaceuticals, INC | $555.24 | 2019-2025 | Linzess |
| Genzyme Corporation | $538.65 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $516.10 | 2019-2024 | Dificid |
| Madrigal Pharmaceuticals | $468.61 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $421.79 | 2023-2025 | Ibsrela |
| Pfizer INC. | $358.17 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $355.86 | 2024-2025 | Voquezna |
| Daiichi Sankyo INC. | $280.27 | 2019-2025 | Injectafer |
| Lilly USA, LLC | $260.88 | 2024-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $226.50 | 2019-2024 | Ocaliva |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $213.02 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $168.01 | 2023-2025 | Dupixent |
| Celgene Corporation | $164.45 | 2022-2024 | Zeposia |
| Qol Medical, LLC | $149.92 | 2024-2025 | Sucraid, Sucraid |
| Redhill Biopharma INC. | $141.74 | 2020-2023 | Movantik, Talicia, Aemcolo |
| Ipsen Biopharmaceuticals, INC | $128.28 | 2024-2025 | Iqirvo |
| Celltrion USA INC. | $121.73 | 2024-2025 | Vegzelma, Zymfentra |
| Organon LLC | $101.48 | 2024-2025 | Hadlima, Renflexis |
| Aimmune Therapeutics, INC. | $56.78 | 2024-2025 | Zenpep |
| Medtronic, INC. | $54.47 | 2023-2024 | Interstim, Signia |
| Fresenius Kabi USA, LLC | $31.58 | 2023 | Idacio |
| Shire North American Group INC | $22.66 | 2019 | |
| Ethicon US, LLC | $20.44 | 2022 | |
| Boston Scientific Corporation | $14.50 | 2021 | |
| Braintree Laboratories, INC. | $12.82 | 2021 | |
| Allergan, INC. | $12.69 | 2019 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.